Synthesis, cytotoxic activity and binding model analysis of novel isoxazole-docetaxel analogues with C3′-N modification
- 42 Downloads
Structure–activity relationship (SAR) studies confirm that modifications at C-3′ position can lead to the development of highly potent novel taxoids. We designed and synthesized a series of novel isoxazole-docetaxel analogues A1–A5 by introducing isoxazolyl groups to C3′-N position. All of the synthesized compounds exhibited similar to better cytotoxic activities than docetaxel against human cancer cell lines, Hela, A2780, A549, MCF-7, and SK-OV-3. These compounds also possessed higher inhibition than docetaxel against drug-resistant cancer cell lines, A2780-MDR and MCF-7-MDR. Binding model analysis of A1–A5 molecule to microtubule (MT) showed that these compounds were anchored to the active site, explaining their inhibitory effects on MT in vitro. The calculated binding free energy values were in positive correlation with the IC50 values of A1–A5 compounds against cancer cells. These results strongly support the statement that the introduction of isoxazolyl groups to C-3′ position indeed improves the cytotoxic activities of taxoids.
KeywordsDocetaxel Isoxazole Cytotoxic Inhibition Binding model analysis
We gratefully acknowledge financial support of this work by the National Natural Science Foundation of China (21172262), the Chinese National Science & Technology Major Project (grants 2010ZXJ0900X-007), the Foundation of the 309th hospital (2015MS-011), the National Natural Science Foundation of China (grant number 21503272) and the General Financial Grant from the China Postdoctoral Science Foundation (grant number 2015M572753).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Case TADDA, Cheatham ITE, Simmerling JWCL (2012) AMBER12. University of California, San FranciscoGoogle Scholar
- DeLano WL (2002) PyMOL molecular graphics system,version 126.96.36.199. LLC, SchrödingerGoogle Scholar
- Georg GI, Boge TC, Cheruvallath ZS, Harriman GCB, Hepperle M, Park H, Himes RH (1994) Cheminform abstract: Schotten-baumann acylation of n-debenzoyltaxol; an efficient route to n-acyl taxol analogues and their biological evaluation. ChemInform 25:no–noGoogle Scholar
- Gunda IG, Zacharia SC, Himes RH, Mejillano MR (1992) Semisynthesis and biological activity of taxol analogues: Baccatin iii 13-(n-benzoyl-(2′r,3′s)-3′-(p-tolyl)isoserinate), baccatin iii 13-(n-(p-toluoyl)-2′r,3′s)-3′-phenylisoserinate), baccatin iii 13-(n-benzoyl-(2′r,3′s) -3′-(p- trifluoromethylphenyl)isoserinate), and baccatin iii 13-(n-(p-trifluoromethylbenzoyl)- (2′r,3′s)-3′-phenyl- isoserinate). Bioorg Med Chem Lett 2:1751–1754CrossRefGoogle Scholar
- Rowbottom MW, Faraoni R, Chao Q, Campbell BT, Lai AG, Setti E, Ezawa M, Sprankle KG, Abraham S, Tran L et al. (2012) Identification of 1-(3-(6,7-dimethoxyquinazolin- 4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropa n-2-yl)isoxazol-3-yl)urea hydrochloride (cep-32496), a highly potent and orally efficacious inhibitor of v-raf murine sarcoma viral oncogene homologueb1 (braf) v600e. J Med Chem 55:1082–1105CrossRefPubMedGoogle Scholar
- Shang YJ, Wang YG (2002) Synthesis of isoxazolines and isoxazoles using poly (ethylene glycol) as Suppor. Synthesis 12:1663–1668Google Scholar
- Swindell CS, Krauss N (2001) Syntheses of taxol, taxol analogs and their intermediates with variable A-ring side chain structures and compositions thereof. US Patent 6262281B1Google Scholar